| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb141b396e502bfce986c491d722e401 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate |
2016-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff1d2ab6775b3cd5e6eea543bb35beca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bd051fd492504efda32fc04237fdd72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeb0864db9dc92e9bb2c2e09bcdf747a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ef1cf0f1ce68f8386c09804fb9417c |
| publicationDate |
2018-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018104232-A1 |
| titleOfInvention |
Methods for determining prognosis for breast cancer patients |
| abstract |
Described herein are methods for treating breast cancer and for providing a prognosis for metastatic-free survival of breast cancer patients. Aspects relate to treating a patient determined to be at high risk for developing or having metastatic breast cancer comprising administering adjuvant or neoadjuvant therapy to the patient determined to be at high risk for developing or having metastatic breast cancer, wherein the patient was determined to be at high risk for developing or having metastatic breast cancer by determining that the expression level of RKIP was reduced and/or the expression level of one or more of HMGA2, CCL5, TN-FR2, GRN, and CCL7 was elevated in a biological sample from the patient compared to a control non-metastatic tissue sample. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020041607-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10888569-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2762317-C1 |
| priorityDate |
2015-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |